Processa Pharmaceuticals develops clinical-stage therapies centered on Next Generation Cancer (NGC) drug products. Company news commonly covers NGC-Cap, its lead oncology asset combining PCS6422 with capecitabine, including clinical updates in advanced or metastatic breast cancer and disclosures on metabolite exposure, safety profile and therapeutic-index objectives.
Updates also address the company's broader pipeline and business priorities, including PCS499 for focal segmental glomerulosclerosis, partnership activity for non-oncology assets, capital actions, conference participation, governance matters and operating or financial results tied to its development-stage biotechnology model.
Processa Pharmaceuticals (Nasdaq: PCSA) announced participation in two upcoming investor conferences, with Executive Chair Sheila Gujrathi scheduled for fireside chats. The UBS Global Healthcare Conference chat is scheduled for November 16 at 4 p.m. GMT, followed by the 9th Annual Evercore ISI HealthCONx Conference chat on December 2 at 12:30 p.m. ET. Management will also host one-on-one investor meetings during the conferences. Live webcasts will be available in the Investors section of the company’s website, with archived replays available after the events.
Processa Pharmaceuticals (PCSA) appointed four executives to leadership roles as it advances its drug-development pipeline for immune-mediated diseases. Gregory J. Flesher becomes Chief Operating Officer; Craig Coburn becomes Executive Vice President, Head of Research; Ashley Hall becomes Executive Vice President, Development; and Michael P. Cruse becomes Executive Vice President, Business Operations.
Processa plans Phase 2 proof-of-concept programs for VT-7208, a Bruton’s tyrosine kinase inhibitor, in food allergy, chronic spontaneous urticaria and relapsing multiple sclerosis. The FDA has cleared the investigational new drug application for the planned chronic spontaneous urticaria study. Processa also announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance a preclinical oral neonatal Fc receptor antagonist program.
Processa Pharmaceuticals (PCSA) received FDA clearance to begin a Phase 2 study of VT-7208 in chronic spontaneous urticaria, following its Vidya acquisition. The planned randomized, double-blind, placebo-controlled trial is expected to enroll approximately 120 adults with moderate-to-severe disease inadequately controlled by H1 antihistamines. It will assess efficacy, safety, tolerability and pharmacologic activity over 12 weeks. Processa also plans Phase 2 studies in food allergy and relapsing multiple sclerosis.
The company entered a research collaboration and exclusive option agreement with Generian Pharmaceuticals for an oral neonatal Fc receptor antagonist program targeting autoimmune diseases. The Vidya acquisition was accompanied by an approximately $200 million private placement; Processa expects current cash to fund operations into the second half of 2029. Sheila Gujrathi was appointed Executive Chair.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage company developing VT-7208, a BTK inhibitor for immune-mediated diseases, will present at two investor conferences. Sheila Gujrathi, M.D., board member and founder and former executive chair of Vidya Therapeutics, will present on September 10 at 10:15 a.m. ET at the Wells Fargo 21st Annual Healthcare Conference and on September 11 at 7:00 a.m. ET at the H.C. Wainwright 28th Annual Global Investment Conference.
In July 2026, Processa announced the stock-for-stock acquisition of Vidya Therapeutics and an oversubscribed private placement of approximately $200 million to advance VT-7208 and fund future operations. A special meeting is planned in Q4 2026 to seek approval for conversion of preferred stock issued in the transaction.
Processa (Nasdaq: PCSA) announced the acquisition of clinical-stage biotech Vidya Therapeutics in a stock-for-stock deal, adding lead asset VT-7208, a next-generation, CNS-penetrant covalent BTK inhibitor being developed for food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS).
Concurrently, Processa entered a definitive agreement for an oversubscribed private placement of approximately $200 million in gross proceeds via Series A non-voting convertible preferred stock, priced at $1,221.19 per preferred share ($1.22119 per common share equivalent). Post-transaction, on a fully diluted basis and assuming full conversion, existing Processa stockholders are expected to own about 0.9% of common stock, Vidya equity holders 46.0%, and private placement investors 52.6%. According to Processa, combined cash, including the financing, is expected to fund operations into the second half of 2029 and through multiple Phase 2 proof-of-concept readouts for VT-7208.
Processa Pharmaceuticals (Nasdaq: PCSA) will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 12-15, 2026. CEO George Ng and Chief Business & Strategy Officer Patrick Lin will be available for one-on-one investor and partner meetings to discuss the company’s clinical pipeline, including the ongoing Phase 2 study of NGC-Cap in advanced or metastatic breast cancer.
Preliminary Phase 2 data reportedly show increased exposure to capecitabine metabolites with a safety profile comparable to capecitabine monotherapy. A formal interim analysis of the first 20 patients is expected in early 2026. Meeting requests can be directed to Wendy Guy at wguy@processapharmaceuticals.com.
Processa Pharmaceuticals (Nasdaq: PCSA) completed enrollment and dosing of the 20 patients required for the planned formal interim analysis in its randomized Phase 2 study of NGC-Cap (PCS6422 + capecitabine) in advanced or metastatic breast cancer.
The formal interim analysis will compare safety and preliminary efficacy versus capecitabine monotherapy and is expected to be completed in Q1 2026. Key interim objectives include evaluating comparative safety/efficacy, deciding whether to add a higher or lower NGC-Cap dose as a third arm, and assessing whether to adjust overall sample size.
Enrolled patients had a median of 2–3 prior treatment regimens. NGC-Cap dosing: single PCS6422 dose one day before capecitabine; capecitabine schedule: 150 mg twice daily, seven days on/seven days off. Mono-Cap dosing: 1,000 mg/m² twice daily, 14 days on/7 days off.
Processa Pharmaceuticals (Nasdaq: PCSA) provided a Phase 2 clinical update for NGC-Cap (PCS6422 + capecitabine) on Dec 17, 2025. Preliminary analysis of the first 16 of 19 randomized patients indicates NGC-Cap increases exposure to capecitabine's active, cancer-killing metabolites while maintaining comparable severity of side effects versus standard capecitabine monotherapy.
Key measured facts: NGC-Cap dosing was 150 mg BID vs Mono-Cap 1,000 mg/m² BID, and exposure to the catabolite FBAL was reduced by up to 10-fold. A formal interim analysis of the first 20 patients is expected in early 2026 with final enrollment targeted by end of Q1 2026.
Processa Pharmaceuticals (Nasdaq: PCSA) announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, was accepted for poster presentation at ASN Kidney Week 2025 in Houston, Nov 5–9, 2025.
The poster is scheduled in the session “Glomerular Clinical Trials: From Data to Impact” on Nov 7, 2025, 10:00–12:00 CT (board FR-PO0829). PCS499 is an analog of a pentoxifylline metabolite that has shown a favorable safety profile versus PTX, potentially allowing higher dosing for greater benefit in rare kidney diseases like FSGS. Processa will discuss an adaptive Phase 2/3 design with the FDA later in 2025 to optimize dosing and accelerate development.
Processa Pharmaceuticals (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on Next Generation Cancer therapies, has announced two strategic initiatives: securing an undisclosed strategic investment and exploring cryptocurrency treasury strategies.
The company is evaluating blockchain-based assets as a potential avenue to diversify its capital base and enhance financial flexibility while funding clinical development programs. This approach aims to reduce shareholder dilution and position Processa at the biotech-fintech intersection.
To implement its cryptocurrency treasury strategy, Processa has engaged LifeSci Capital, LLC as an advisor.